Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Celldex Therapeutics (CLDX) over the last 14 years, with Q3 2025 value amounting to $5.1 million.

  • Celldex Therapeutics' Non-cash Items fell 9399.25% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 9399.25%. This contributed to the annual value of $4.0 million for FY2024, which is 2203.25% up from last year.
  • Latest data reveals that Celldex Therapeutics reported Non-cash Items of $5.1 million as of Q3 2025, which was down 9399.25% from $4.9 million recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' Non-cash Items registered a high of $122.6 million during Q4 2022, and its lowest value of $3.3 million during Q4 2023.
  • Moreover, its 5-year median value for Non-cash Items was $38.3 million (2023), whereas its average is $44.7 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first surged by 428203.03% in 2021, then tumbled by 9733.94% in 2023.
  • Quarter analysis of 5 years shows Celldex Therapeutics' Non-cash Items stood at $84.7 million in 2021, then skyrocketed by 44.75% to $122.6 million in 2022, then plummeted by 97.34% to $3.3 million in 2023, then rose by 22.03% to $4.0 million in 2024, then increased by 28.89% to $5.1 million in 2025.
  • Its Non-cash Items stands at $5.1 million for Q3 2025, versus $4.9 million for Q2 2025 and $4.2 million for Q1 2025.